HCA Healthcare Inc. (NYSE:HCA) went up by 0.86% from its latest closing price compared to the recent 1-year high of $217.36. The company’s stock price has collected -1.48% of loss in the last five trading sessions. The Wall Street Journal reported on 05/28/21 that Exxon, Amazon, Ford, Best Buy: Stocks That Defined the Week
Is It Worth Investing in HCA Healthcare Inc. (NYSE :HCA) Right Now?
HCA Healthcare Inc. (NYSE:HCA) scored a price-to-earnings ratio above its average ratio, recording 15.70 x from its present earnings ratio. Plus, the 36-month beta value for HCA is at 1.65. Opinions of the stock are interesting as 16 analysts out of 23 who provided ratings for HCA Healthcare Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 5 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $222.55, which is $12.35 above the current price. HCA currently public float of 265.00M and currently shorts hold a 1.21% ratio of that float. Today, the average trading volume of HCA was 1.44M shares.
HCA’s Market Performance
HCA stocks went down by -1.48% for the week, with a monthly jump of 1.62% and a quarterly performance of 13.43%, while its annual performance rate touched 90.84%. The volatility ratio for the week stands at 1.58% while the volatility levels for the past 30 days are set at 1.96% for HCA Healthcare Inc.. The simple moving average for the period of the last 20 days is 0.18% for HCA stocks with a simple moving average of 25.90% for the last 200 days.
Analysts’ Opinion of HCA
Many brokerage firms have already submitted their reports for HCA stocks, with Citigroup repeating the rating for HCA by listing it as a “Neutral.” The predicted price for HCA in the upcoming period, according to Citigroup is $215 based on the research report published on May 13th of the current year 2021.
Citigroup, on the other hand, stated in their research note that they expect to see HCA reach a price target of $215, previously predicting the price at $191. The rating they have provided for HCA stocks is “Neutral” according to the report published on April 26th, 2021.
Goldman gave a rating of “Buy” to HCA, setting the target price at $191 in the report published on December 15th of the previous year.
HCA Trading at 3.94% from the 50-Day Moving Average
After a stumble in the market that brought HCA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.34% of loss for the given period.
Volatility was left at 1.96%, however, over the last 30 days, the volatility rate increased by 1.58%, as shares surge +2.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.44% upper at present.
During the last 5 trading sessions, HCA fell by -1.48%, which changed the moving average for the period of 200-days by +56.35% in comparison to the 20-day moving average, which settled at $210.02. In addition, HCA Healthcare Inc. saw 27.75% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at HCA starting from Reiner Deborah M, who sale 3,432 shares at the price of $208.33 back on May 11. After this action, Reiner Deborah M now owns 6,576 shares of HCA Healthcare Inc., valued at $714,989 using the latest closing price.
Paslick P. Martin, the SVP and CIO of HCA Healthcare Inc., sale 7,672 shares at $207.55 during a trade that took place back on May 06, which means that Paslick P. Martin is holding 12,878 shares at $1,592,324 based on the most recent closing price.
Stock Fundamentals for HCA
Current profitability levels for the company are sitting at:
- +14.09 for the present operating margin
- +14.09 for the gross margin
The net margin for HCA Healthcare Inc. stands at +7.28. The total capital return value is set at 20.47, while invested capital returns managed to touch 11.50. Equity return is now at value -947.10, with 9.50 for asset returns.
Based on HCA Healthcare Inc. (HCA), the company’s capital structure generated 5,779.02 points at debt to equity in total, while total debt to capital is 98.30. Total debt to assets is 69.61, with long-term debt to equity ratio resting at 5,676.22. Finally, the long-term debt to capital ratio is 96.55.
When we switch over and look at the enterprise to sales, we see a ratio of 1.75, with the company’s debt to enterprise value settled at 0.37. The receivables turnover for the company is 7.13 and the total asset turnover is 1.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.42.